Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting ; volume:17 ; number:1 ; day:6 ; month:5 ; year:2024 ; pages:1-7 ; date:12.2024
Journal of hematology & oncology ; 17, Heft 1 (6.5.2024), 1-7, 12.2024
- Creator
-
Kang, Yun
Li, Chenggong
Mei, Heng
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-024-01550-9
- URN
-
urn:nbn:de:101:1-2407152122216.384399645944
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kang, Yun
- Li, Chenggong
- Mei, Heng
- SpringerLink (Online service)
Other Objects (12)
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Engineering CAR-T cells
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Engineering CAR-T cells
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Engineering CAR-T cells
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma